Triple-negative breast cancer is more common in younger women than in all breast cancer patients, and the risk of developing triple-negative breast cancer is twice as high in women under age 40 as in women over age 50.
In addition, mutations in the breast cancer susceptibility gene (BRCA) are also considered a risk factor for triple-negative breast cancer. One study showed that about 20% of triple-negative breast cancer patients have BRCA mutations, especially BRCA1 mutations, and less than 6% of all breast cancer patients are associated with BRCA mutations.
Surgery is a necessary treatment for all operable breast cancers, and chemotherapy and radiation therapy are also required depending on the disease. Patients with triple-negative breast cancer do not need endocrine therapy or Herceptin therapy. Breast-conserving surgery is available for patients with triple-negative breast cancer, and breast-conserving surgery does not affect prognosis.
The prognosis for patients with triple-negative breast cancer varies from patient to patient, and the reasons for this need to be further explored, and new drugs for triple-negative breast cancer are expected to be available as soon as possible to bring benefit to patients with triple-negative breast cancer.
Statistics show that triple-negative breast cancer has a peak mortality rate in the first 2 years of diagnosis, with a rapid decline thereafter. Therefore, after a diagnosis of triple-negative breast cancer, patients must actively cooperate with their doctors to complete all treatments and maintain a good mindset to achieve the best results.